Health Care & Life Sciences » Pharmaceuticals | Relevium Technologies Inc.

Relevium Technologies Inc. | Income Statement

Fiscal year is July-June. All values CAD Thousands.
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
80.40
72.30
2,020.90
Gross Income
-
80.40
72.30
2,131.90
SG&A Expense
206.60
955.20
1,728.60
4,277.10
EBIT
206.60
1,035.60
1,801.00
2,145.20
Unusual Expense
-
525.30
747.30
102.50
Non Operating Income/Expense
-
3.60
2.20
8
Interest Expense
0.20
-
34.30
858.10
Pretax Income
193.40
1,557.70
2,584.70
2,892.70
Consolidated Net Income
193.40
1,557.70
2,584.70
2,892.70
Net Income
193.40
1,557.70
2,584.70
2,892.70
Net Income After Extraordinaries
193.40
1,557.70
2,584.70
2,892.70
Net Income Available to Common
193.40
1,557.70
2,584.70
2,892.70
EPS (Basic)
0.03
0.06
0.07
0.04
Basic Shares Outstanding
5,898.00
27,637.70
35,956.30
78,691.50
EPS (Diluted)
0.03
0.06
0.07
0.04
Diluted Shares Outstanding
5,898.00
27,637.70
35,956.30
78,691.50
EBITDA
206.60
955.20
1,728.60
1,997.60
Non-Operating Interest Income
13.30
6.70
0.00
-

About Relevium Technologies

View Profile
Address
1000 Sherbrooke Street West
Montréal Québec H3A 3G4
Canada
Employees -
Website http://www.releviumcorp.com
Updated 07/08/2019
Relevium Technologies, Inc. develops medical devices for magnetic therapy. It focuses in musculoskeletal function specifically in the areas of pain relief, recovery and performance enhancement. The company was founded on July 19, 2012 and is headquartered in Montréal, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.